Tissue Regenix Group PLC Directorate Change (4237Q)
February 26 2021 - 01:00AM
UK Regulatory
TIDMTRX
RNS Number : 4237Q
Tissue Regenix Group PLC
26 February 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Directorate Change
Leeds, 26 February 2021 - Tissue Regenix (AIM: TRX), the
regenerative medical devices company, announces that the Board has
appointed Jonathan Glenn, current Interim Non-Executive Chairman,
to the position of Non-Executive Chairman with immediate
effect.
Jonathan joined the Group in January 2016, and was appointed
Interim Non-Executive Chairman in March 2020.
Daniel Lee, Chief Executive Officer, of Tissue Regenix Group plc
said: "We are delighted to have Jonathan appointed as Non-Executive
Chairman to the Group. Jonathan's leadership has been invaluable
over the last year, as Interim Chairman, and we look forward to his
continued contribution towards the Company's future growth."
For more Information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Tel: +44(0)20 7710
Adviser and Broker) 7600
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933
Alice Woodings / Lianne Cawthorne / Paul 8780
McManus TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUQGPUPGGRA
(END) Dow Jones Newswires
February 26, 2021 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2023 to Mar 2024